[논문]Advances in Universal CAR-T Cell Therapy

Lin, Haolong; Cheng, Jiali; Mu, Wei; Zhou, Jianfeng; Zhu, Li

doi:10.3389/fimmu.2021.744823

[해외논문] Advances in Universal CAR-T Cell Therapy 원문보기

Frontiers in immunology, v.12, 2021년, pp.744823 -

Lin, Haolong , Cheng, Jiali , Mu, Wei , Zhou, Jianfeng , Zhu, Li

Abstract ▼ AI-Helper

Chimeric antigen receptor T (CAR-T) cell therapy achieved extraordinary achievements results in antitumor treatments, especially against hematological malignancies, where it leads to remarkable, long-term antineoplastic effects with higher target specificity. Nevertheless, some limitations persist in autologous CAR-T cell therapy, such as high costs, long manufacturing periods, and restricted cell sources. The development of a universal CAR-T (UCAR-T) cell therapy is an attractive breakthrough point that may overcome most of these drawbacks. Here, we review the progress and challenges in CAR-T cell therapy, especially focusing on comprehensive comparison in UCAR-T cell therapy to original CAR-T cell therapy. Furthermore, we summarize the developments and concerns about the safety and efficiency of UCAR-T cell therapy. Finally, we address other immune cells, which might be promising candidates as a complement for UCAR-T cells. Through a detailed overview, we describe the current landscape and explore the prospect of UCAR-T cell therapy.

Keyword

참고문헌 (84)

1 Yu JX Upadhaya S Tatake R Barkalow F Hubbard-Lucey VM . Cancer Cell Therapies: The Clinical Trial Landscape . Nat Rev Drug Discov ( 2020 ) 19 : 583？4 . doi:？ 10.1038/d41573-020-00099-9

상세보기
2 Labanieh L Majzner RG Mackall CL . Programming CAR-T Cells to Kill Cancer . Nat BioMed Eng ( 2018 ) 2 : 377？91 . doi:？ 10.1038/s41551-018-0235-9

상세보기
3 Sadelain M Brentjens R Riviere I . The Promise and Potential Pitfalls of Chimeric Antigen Receptors . Curr Opin Immunol ( 2009 ) 21 : 215？23 . doi:？ 10.1016/j.coi.2009.02.009

상세보기
4 June CH Sadelain M . Chimeric Antigen Receptor Therapy . N Engl J Med ( 2018 ) 379 : 64 ？ 73 . doi:？ 10.1056/NEJMra1706169 29972754

상세보기
5 Zhao J Lin Q Song Y Liu D . Universal CARs, Universal T Cells, and Universal CAR T Cells . J Hematol Oncol ( 2018 ) 11 : 132 . doi:？ 10.1186/s13045-018-0677-2 30482221

상세보기
6 Huang R Li X He Y Zhu W Gao L Liu Y . Recent Advances in CAR-T Cell Engineering . J Hematol Oncol ( 2020 ) 13 : 86 . doi:？ 10.1186/s13045-020-00910-5 32616000

상세보기
7 Yu S Yi M Qin S Wu K . Next Generation Chimeric Antigen Receptor T Cells: Safety Strategies to Overcome Toxicity . Mol Cancer ( 2019 ) 18 : 125 . doi:？ 10.1186/s12943-019-1057-4 31429760

상세보기
8 Chmielewski M Abken H . TRUCKs: The Fourth Generation of CARs . Expert Opin Biol Ther ( 2015 ) 15 : 1145？54 . doi:？ 10.1517/14712598.2015.1046430

상세보기
9 Schuster SJ Bishop MR Tam CS Waller EK Borchmann P Mcguirk JP . Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma . N Engl J Med ( 2019 ) 380 : 45 ？ 56 . doi:？ 10.1056/NEJMoa1804980 30501490

상세보기
10 Neelapu SS Locke FL Bartlett NL Lekakis LJ Miklos DB Jacobson CA . Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma . N Engl J Med ( 2017 ) 377 : 2531？44 . doi:？ 10.1056/NEJMoa1707447

상세보기
11 Singh N Orlando E Xu J Xu J Binder Z Collins MA . Mechanisms of Resistance to CAR T Cell Therapies . Semin Cancer Biol ( 2020 ) 65 : 91？8 . doi:？ 10.1016/j.semcancer.2019.12.002

상세보기
12 Brudno JN Kochenderfer JN . Recent Advances in CAR T-Cell Toxicity: Mechanisms, Manifestations and Management . Blood Rev ( 2019 ) 34 : 45 ？ 55 . doi:？ 10.1016/j.blre.2018.11.002 30528964

상세보기
13 Drent E Themeli M Poels R De Jong-Korlaar R Yuan H De Bruijn J . A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization . Mol Ther ( 2017 ) 25 : 1946？58 . doi:？ 10.1016/j.ymthe.2017.04.024

상세보기
14 Lin JK Lerman BJ Barnes JI Boursiquot BC Tan YJ Robinson AQL . Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia . J Clin Oncol ( 2018 ) 36 : 3192？202 . doi:？ 10.1200/JCO.2018.79.0642

상세보기
15 Siegler EL Zhu Y Wang P Yang L . Off-The-Shelf CAR-NK Cells for Cancer Immunotherapy . Cell Stem Cell ( 2018 ) 23 : 160？1 . doi:？ 10.1016/j.stem.2018.07.007

상세보기
16 Ruella M Xu J Barrett DM Fraietta JA Reich TJ Ambrose DE . Induction of Resistance to Chimeric Antigen Receptor T Cell Therapy by Transduction of a Single Leukemic B Cell . Nat Med ( 2018 ) 24 : 1499？503 . doi:？ 10.1038/s41591-018-0201-9

상세보기
17 Ma X Shou P Smith C Chen Y Du H Sun C . Interleukin-23 Engineering Improves CAR T Cell Function in Solid Tumors . Nat Biotechnol ( 2020 ) 38 : 448？59 . doi:？ 10.1038/s41587-019-0398-2

상세보기
18 Depil S Duchateau P Grupp SA Mufti G Poirot L . Off-the-Shelf' Allogeneic CAR T Cells: Development and Challenges . Nat Rev Drug Discov ( 2020 ) 19 : 185？99 . doi:？ 10.1038/s41573-019-0051-2

상세보기
19 Kochenderfer JN Dudley ME Carpenter RO Kassim SH Rose JJ Telford WG . Donor-Derived CD19-Targeted T Cells Cause Regression of Malignancy Persisting After Allogeneic Hematopoietic Stem Cell Transplantation . Blood ( 2013 ) 122 : 4129？39 . doi:？ 10.1182/blood-2013-08-519413

상세보기
20 Brudno JN Somerville RP Shi V Rose JJ Halverson DC Fowler DH . Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease . J Clin Oncol ( 2016 ) 34 : 1112？21 . doi:？ 10.1200/JCO.2015.64.5929

상세보기
21 Dai H Zhang W Li X Han Q Guo Y Zhang Y . Tolerance and Efficacy of Autologous or Donor-Derived T Cells Expressing CD19 Chimeric Antigen Receptors in Adult B-ALL With Extramedullary Leukemia . Oncoimmunology ( 2015 ) 4 : e1027469 . doi:？ 10.1080/2162402X.2015.1027469 26451310

상세보기
22 Hu Y Wang J Wei G Yu J Luo Y Shi J . A Retrospective Comparison of Allogenic and Autologous Chimeric Antigen Receptor T Cell Therapy Targeting CD19 in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia . Bone Marrow Transplant ( 2019 ) 54 : 1208？17 . doi:？ 10.1038/s41409-018-0403-2

상세보기
23 Ghosh A Smith M James SE Davila ML Velardi E Argyropoulos KV . Donor CD19 CAR T Cells Exert Potent Graft-Versus-Lymphoma Activity With Diminished Graft-Versus-Host Activity . Nat Med ( 2017 ) 23 : 242？9 . doi:？ 10.1038/nm.4258

상세보기
24 Jacoby E Yang Y Qin H Chien CD Kochenderfer JN Fry TJ . Murine Allogeneic CD19 CAR T Cells Harbor Potent Antileukemic Activity But Have the Potential to Mediate Lethal GVHD . Blood ( 2016 ) 127 : 1361？70 . doi:？ 10.1182/blood-2015-08-664250

상세보기
25 Morgan MA Buning H Sauer M Schambach A . Use of Cell and Genome Modification Technologies to Generate Improved “Off-The-Shelf” CAR T and CAR NK Cells . Front Immunol ( 2020 ) 11 : 1965 . doi:？ 10.3389/fimmu.2020.01965 32903482

상세보기
26 Cooper ML Dipersio JF . Chimeric Antigen Receptor T Cells (CAR-T) for the Treatment of T-Cell Malignancies . Best Pract Res Clin Haematol ( 2019 ) 32 : 101097 . doi:？ 10.1016/j.beha.2019.101097 31779968

상세보기
27 Ren J Liu X Fang C Jiang S June CH Zhao Y . Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition . Clin Cancer Res ( 2017 ) 23 : 2255？66 . doi:？ 10.1158/1078-0432.CCR-16-1300

상세보기
28 Li S Wang X Yuan Z Liu L Luo L Li Y . Eradication of T-ALL Cells by CD7-Targeted Universal CAR-T Cells and Initial Test of Ruxolitinib-Based CRS Management . Clin Cancer Res ( 2021 ) 27 : 1242？6 . doi:？ 10.1158/1078-0432.CCR-20-1271

상세보기
29 Feldmann A Arndt C Koristka S Berndt N Bergmann R Bachmann MP . Conventional CARs Versus Modular CARs . Cancer Immunol Immunother ( 2019 ) 68 : 1713？9 . doi:？ 10.1007/s00262-019-02399-5

상세보기
30 Martinez Bedoya D Dutoit V Migliorini D . Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma . Front Immunol ( 2021 ) 12 : 640082 . doi:？ 10.3389/fimmu.2021.640082 33746981

상세보기
31 Benjamin R Graham C Yallop D Jozwik A Mirci-Danicar OC Lucchini G . Genome-Edited, Donor-Derived Allogeneic Anti-CD19 Chimeric Antigen Receptor T Cells in Paediatric and Adult B-Cell Acute Lymphoblastic Leukaemia: Results of Two Phase 1 Studies . Lancet ( 2020 ) 396 : 1885？94 . doi:？ 10.1016/S0140-6736(20)32334-5

상세보기
32 Qasim W Zhan H Samarasinghe S Adams S Amrolia P Stafford S . Molecular Remission of Infant B-ALL After Infusion of Universal TALEN Gene-Edited CAR T Cells . Sci Transl Med ( 2017 ) 9 : eaaj2013 . doi:？ 10.1126/scitranslmed.aaj2013 28123068

상세보기
33 Hu Y Zhou Y Zhang M Ge W Li Y Yang L . CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia . Clin Cancer Res ( 2021 ) 27 : 27647？72 . doi:？ 10.1158/1078-0432.CCR-20-3863

상세보기
34 Wang W Fasolino M Cattau B Goldman N Kong W Frederick MA . Joint Profiling of Chromatin Accessibility and CAR-T Integration Site Analysis at Population and Single-Cell Levels . Proc Natl Acad Sci USA ( 2020 ) 117 : 5442？52 . doi:？ 10.1073/pnas.1919259117

상세보기
35 Torikai H Reik A Liu PQ Zhou Y Zhang L Maiti S . A Foundation for Universal T-Cell Based Immunotherapy: T Cells Engineered to Express a CD19-Specific Chimeric-Antigen-Receptor and Eliminate Expression of Endogenous TCR . Blood ( 2012 ) 119 : 5697？705 . doi:？ 10.1182/blood-2012-01-405365

상세보기
36 Poirot L Philip B Schiffer-Mannioui C Le Clerre D Chion-Sotinel I Derniame S . Multiplex Genome-Edited T-Cell Manufacturing Platform for "Off-The-Shelf" Adoptive T-Cell Immunotherapies . Cancer Res ( 2015 ) 75 : 3853？64 . doi:？ 10.1158/0008-5472.CAN-14-3321

상세보기
37 Mollanoori H Shahraki H Rahmati Y Teimourian S . CRISPR/Cas9 and CAR-T Cell, Collaboration of Two Revolutionary Technologies in Cancer Immunotherapy, an Instruction for Successful Cancer Treatment . Hum Immunol ( 2018 ) 79 : 876？82 . doi:？ 10.1016/j.humimm.2018.09.007

상세보기
38 Eyquem J Mansilla-Soto J Giavridis T van der Stegen SJ Hamieh M Cunanan KM . Targeting a CAR to the TRAC Locus With CRISPR/Cas9 Enhances Tumour Rejection . Nature ( 2017 ) 543 : 113？7 . doi:？ 10.1038/nature21405

상세보기
39 Urbanska K Lanitis E Poussin M Lynn RC Gavin BP Kelderman S . A Universal Strategy for Adoptive Immunotherapy of Cancer Through Use of a Novel T-Cell Antigen Receptor . Cancer Res ( 2012 ) 72 : 1844？52 . doi:？ 10.1158/0008-5472.CAN-11-3890

상세보기
40 Sutherland AR Owens MN Geyer CR . Modular Chimeric Antigen Receptor Systems for Universal CAR T Cell Retargeting . Int J Mol Sci ( 2020 ) 21 : 7222 . doi:？ 10.3390/ijms21197222

상세보기
41 Loff S Dietrich J Meyer JE Riewaldt J Spehr J Von Bonin M . Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia . Mol Ther Oncolytics ( 2020 ) 17 : 408？20 . doi:？ 10.1016/j.omto.2020.04.009

상세보기
42 Zhang B Wang Y Huang S Sun J Wang M Ma W . Photoswitchable CAR-T Cell Function In Vitro and In Vivo via a Cleavable Mediator . Cell Chem Biol ( 2021 ) 28 : 60 ？ 69.e67 . doi:？ 10.1016/j.chembiol.2020.10.004 33113407

상세보기
43 Cartellieri M Feldmann A Koristka S Arndt C Loff S Ehninger A . Switching CAR T Cells on and Off: A Novel Modular Platform for Retargeting of T Cells to AML Blasts . Blood Cancer J ( 2016 ) 6 : e458 . doi:？ 10.1038/bcj.2016.61 27518241

상세보기
44 Wermke M Kraus S Ehninger A Bargou RC Goebeler ME Middeke JM . Proof-Of-Concept for Rapidly Switchable Universal CAR-T Platform With UniCAR-T-CD123 in Relapsed/Refractory AML . Blood ( 2021 ) 137 : 3145？48 . doi:？ 10.1182/blood.2020009759

상세보기
45 Kloss CC Condomines M Cartellieri M Bachmann M Sadelain M . Combinatorial Antigen Recognition With Balanced Signaling Promotes Selective Tumor Eradication by Engineered T Cells . Nat Biotechnol ( 2013 ) 31 : 71？5 . doi:？ 10.1038/nbt.2459

상세보기
46 Lanitis E Poussin M Klattenhoff AW Song D Sandaltzopoulos R June CH . Chimeric Antigen Receptor T Cells With Dissociated Signaling Domains Exhibit Focused Antitumor Activity With Reduced Potential for Toxicity In Vivo . Cancer Immunol Res ( 2013 ) 1 : 43 ？ 53 . doi:？ 10.1158/2326-6066.CIR-13-0008 24409448

상세보기
47 Cho JH Collins JJ Wong WW . Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses . Cell ( 2018 ) 173 : 1426 ？ 38.e1411 . doi:？ 10.1016/j.cell.2018.03.038 29706540

상세보기
48 Cerrano M Ruella M Perales MA Vitale C Faraci DG Giaccone L . The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice . Front Immunol ( 2020 ) 11 : 888 . doi:？ 10.3389/fimmu.2020.00888 32477359

상세보기
49 Li L Hu S Chen X . Non-Viral Delivery Systems for CRISPR/Cas9-Based Genome Editing: Challenges and Opportunities . Biomaterials ( 2018 ) 171 : 207？18 . doi:？ 10.1016/j.biomaterials.2018.04.031

상세보기
50 Valton J Guyot V Marechal A Filhol JM Juillerat A Duclert A . A Multidrug-Resistant Engineered CAR T Cell for Allogeneic Combination Immunotherapy . Mol Ther ( 2015 ) 23 : 1507？18 . doi:？ 10.1038/mt.2015.104

상세보기
51 Watts TH . TNF/TNFR Family Members in Costimulation of T Cell Responses . Annu Rev Immunol ( 2005 ) 23 : 23 ？ 68 . doi:？ 10.1146/annurev.immunol.23.021704.115839 15771565

상세보기
52 Chester C Sanmamed MF Wang J Melero I . Immunotherapy Targeting 4-1BB: Mechanistic Rationale, Clinical Results, and Future Strategies . Blood ( 2018 ) 131 : 49 ？ 57 . doi:？ 10.1182/blood-2017-06-741041 29118009

상세보기
53 Mo F Watanabe N Mckenna MK Hicks MJ Srinivasan M Gomes-Silva D . Engineered Off-the-Shelf Therapeutic T Cells Resist Host Immune Rejection . Nat Biotechnol ( 2021 ) 39 : 56 ？ 63 . doi:？ 10.1038/s41587-020-0601-5 32661440

상세보기
54 Braud VM Allan DS O'callaghan CA Soderstrom K D'andrea A Ogg GS . HLA-E Binds to Natural Killer Cell Receptors CD94/NKG2A, B and C . Nature ( 1998 ) 391 : 795？9 . doi:？ 10.1038/35869

상세보기
55 Krawczyk M Peyraud N Rybtsova N Masternak K Bucher P Barras E . Long Distance Control of MHC Class II Expression by Multiple Distal Enhancers Regulated by Regulatory Factor X Complex and CIITA . J Immunol ( 2004 ) 173 : 6200？10 . doi:？ 10.4049/jimmunol.173.10.6200

상세보기
56 Watanabe N Mamonkin M . Off-The-Shelf Chimeric Antigen Receptor T Cells: How Do We Get There ? Cancer J ( 2021 ) 27 : 176？81 . doi:？ 10.1097/PPO.0000000000000511

상세보기
57 Kagoya Y Guo T Yeung B Saso K Anczurowski M Wang CH . Genetic Ablation of HLA Class I, Class II, and the T-Cell Receptor Enables Allogeneic T Cells to Be Used for Adoptive T-Cell Therapy . Cancer Immunol Res ( 2020 ) 8 : 926？36 . doi:？ 10.1158/2326-6066.CIR-18-0508

상세보기
58 Wang B Iriguchi S Waseda M Ueda N Ueda T Xu H . Generation of Hypoimmunogenic T Cells From Genetically Engineered Allogeneic Human Induced Pluripotent Stem Cells . Nat BioMed Eng ( 2021 ) 5 : 429？40 . doi:？ 10.1038/s41551-021-00730-z

상세보기
59 Lin C Zhang J . Chimeric Antigen Receptor Engineered Innate Immune Cells in Cancer Immunotherapy . Sci China Life Sci ( 2019 ) 62 : 633？9 . doi:？ 10.1007/s11427-018-9451-0

상세보기
60 Zhao Y Niu C Cui J . Gamma-Delta (γδ) T Cells: Friend or Foe in Cancer Development ? J Transl Med ( 2018 ) 16 : 3 . doi:？ 10.1186/s12967-018-1491-x 29316940

상세보기
61 Perez C Gruber I Arber C . Off-The-Shelf Allogeneic T Cell Therapies for Cancer: Opportunities and Challenges Using Naturally Occurring "Universal" Donor T Cells . Front Immunol ( 2020 ) 11 : 583716 . doi:？ 10.3389/fimmu.2020.583716 33262761

상세보기
62 Di Lorenzo B Simoes AE Caiado F Tieppo P Correia DV Carvalho T . Broad Cytotoxic Targeting of Acute Myeloid Leukemia by Polyclonal Delta One T Cells . Cancer Immunol Res ( 2019 ) 7 : 552？8 . doi:？ 10.1158/2326-6066.CIR-18-0647

상세보기
63 Sebestyen Z Prinz I Dechanet-Merville J Silva-Santos B Kuball J . Translating Gammadelta (γδ) T Cells and Their Receptors Into Cancer Cell Therapies . Nat Rev Drug Discov ( 2020 ) 19 : 169？84 . doi:？ 10.1038/s41573-019-0038-z

상세보기
64 Capsomidis A Benthall G Van Acker HH Fisher J Kramer AM Abeln Z . Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity With Retention of Cross Presentation . Mol Ther ( 2018 ) 26 : 354？65 . doi:？ 10.1016/j.ymthe.2017.12.001

상세보기
65 Wolf BJ Choi JE Exley MA . Novel Approaches to Exploiting Invariant NKT Cells in Cancer Immunotherapy . Front Immunol ( 2018 ) 9 : 384 . doi:？ 10.3389/fimmu.2018.00384 29559971

상세보기
66 Simon B Wiesinger M Marz J Wistuba-Hamprecht K Weide B Schuler-Thurner B . The Generation of CAR-Transfected Natural Killer T Cells for the Immunotherapy of Melanoma . Int J Mol Sci ( 2018 ) 19 : 2365 . doi:？ 10.3390/ijms19082365

상세보기
67 Pillai AB George TI Dutt S Teo P Strober S . Host NKT Cells can Prevent Graft-Versus-Host Disease and Permit Graft Antitumor Activity After Bone Marrow Transplantation . J Immunol ( 2007 ) 178 : 6242？51 . doi:？ 10.4049/jimmunol.178.10.6242

상세보기
68 Heczey A Courtney AN Montalbano A Robinson S Liu K Li M . Anti-GD2 CAR-NKT Cells in Patients With Relapsed or Refractory Neuroblastoma: An Interim Analysis . Nat Med ( 2020 ) 26 : 1686？90 . doi:？ 10.1038/s41591-020-1074-2

상세보기
69 Xu X Huang W Heczey A Liu D Guo L Wood M . NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced In Vivo Persistence and Antitumor Activity Against Neuroblastoma . Clin Cancer Res ( 2019 ) 25 : 7126？38 . doi:？ 10.1158/1078-0432.CCR-19-0421

상세보기
70 Caldwell KJ Gottschalk S Talleur AC . Allogeneic CAR Cell Therapy-More Than a Pipe Dream . Front Immunol ( 2020 ) 11 : 618427 . doi:？ 10.3389/fimmu.2020.618427 33488631

상세보기
71 Zhang Q Lu W Liang CL Chen Y Liu H Qiu F . Chimeric Antigen Receptor (CAR) Treg: A Promising Approach to Inducing Immunological Tolerance . Front Immunol ( 2018 ) 9 : 2359 . doi:？ 10.3389/fimmu.2018.02359 30369931

상세보기
72 Fritsche E Volk HD Reinke P Abou-El-Enein M . Toward an Optimized Process for Clinical Manufacturing of CAR-Treg Cell Therapy . Trends Biotechnol ( 2020 ) 38 : 1099？112 . doi:？ 10.1016/j.tibtech.2019.12.009

상세보기
73 Xie G Dong H Liang Y Ham JD Rizwan R Chen J . CAR-NK Cells: A Promising Cellular Immunotherapy for Cancer . EBioMedicine ( 2020 ) 59 : 102975 . doi:？ 10.1016/j.ebiom.2020.102975 32853984

상세보기
74 Rezvani K Rouce R Liu E Shpall E . Engineering Natural Killer Cells for Cancer Immunotherapy . Mol Ther ( 2017 ) 25 : 1769？81 . doi:？ 10.1016/j.ymthe.2017.06.012

상세보기
75 Wang W Jiang J Wu C . CAR-NK for Tumor Immunotherapy: Clinical Transformation and Future Prospects . Cancer Lett ( 2020 ) 472 : 175？80 . doi:？ 10.1016/j.canlet.2019.11.033

상세보기
76 Liu E Marin D Banerjee P Macapinlac HA Thompson P Basar R . Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors . N Engl J Med ( 2020 ) 382 : 545？53 . doi:？ 10.1056/NEJMoa1910607

상세보기
77 Nianias A Themeli M . Induced Pluripotent Stem Cell (iPSC)-Derived Lymphocytes for Adoptive Cell Immunotherapy: Recent Advances and Challenges . Curr Hematol Malig Rep ( 2019 ) 14 : 261？8 . doi:？ 10.1007/s11899-019-00528-6

상세보기
78 Sachamitr P Hackett S Fairchild PJ . Induced Pluripotent Stem Cells: Challenges and Opportunities for Cancer Immunotherapy . Front Immunol ( 2014 ) 5 : 176 . doi:？ 10.3389/fimmu.2014.00176 24860566

상세보기
79 Clarke R van der Stegen S Chang C-W Husain M Lai Y-S Peralta E . Pluripotent Cell-Derived Off-The-Shelf TCR-Less CAR-Targeted Cytotoxic T Cell Therapeutic for the Allogeneic Treatment of B Cell Malignancies . Blood ( 2018 ) 132 : 4546 . doi:？ 10.1182/blood-2018-99-116843

상세보기
80 Themeli M Kloss CC Ciriello G Fedorov VD Perna F Gonen M . Generation of Tumor-Targeted Human T Lymphocytes From Induced Pluripotent Stem Cells for Cancer Therapy . Nat Biotechnol ( 2013 ) 31 : 928？33 . doi:？ 10.1038/nbt.2678

상세보기
81 Li Y Hermanson DL Moriarity BS Kaufman DS . Human iPSC-Derived Natural Killer Cells Engineered With Chimeric Antigen Receptors Enhance Anti-Tumor Activity . Cell Stem Cell ( 2018 ) 23 : 181 ？ 92.e185 . doi:？ 10.1016/j.stem.2018.06.002 30082067

상세보기
82 Long KB Beatty GL . Harnessing the Antitumor Potential of Macrophages for Cancer Immunotherapy . Oncoimmunology ( 2013 ) 2 : e26860 . doi:？ 10.4161/onci.26860 24498559

상세보기
83 Niu Z Chen G Chang W Sun P Luo Z Zhang H . Chimeric Antigen Receptor-Modified Macrophages Trigger Systemic Anti-Tumour Immunity . J Pathol ( 2021 ) 253 : 247？57 . doi:？ 10.1002/path.5585

상세보기
84 Klichinsky M Ruella M Shestova O Lu XM Best A Zeeman M . Human Chimeric Antigen Receptor Macrophages for Cancer Immunotherapy . Nat Biotechnol ( 2020 ) 38 : 947？53 . doi:？ 10.1038/s41587-020-0462-y

상세보기

활용도 분석정보

상세보기

다운로드

내보내기

활용도 Top5 논문

해당 논문의 주제분야에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.

표제어: PCR

동의어: Packet Collision Rate

용어 설명 출처 목록 (6)

용어 설명: PCR은 세균 특이성이 있는 primer를 이용하여 적은 수의 세균이 있을지라도 쉽게 검출할 수 있는 유용한 방법이며, 이를 이용하여 구강 내 치면세균막이나 타액에서 직접 세균을 검출할 수 있게 되었다[8].

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증